<div class="headers"><div>Figure 2 (A) ASAS20 and (B) ASAS40 response rates at week 12 in
BUILDER-1 part 1 (intention-to-treat population; significance was
determined using a logistic regression adjusted for region) for the entire group and (C) by CRP levels at baseline. ASAS20, 20% improvement in the Assessments in Ankylosing Spondylitis Response Criteria; CRP, C
reactive protein; TCZ, tocilizumab; ULN, upper limit of normal.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='text-align: left;'>1</td>
<td style='text-align: left;'>1</td>
<td style='text-align: left;'><p class="">Figure 2 (A) ASAS20 and (B) ASAS40 response rates at week 12 in
BUILDER-1 part 1 (intention-to-treat population; significance was
determined using a logistic regression adjusted for region) for the entire group and (C) by CRP levels at baseline. </p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>2</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>2</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">ASAS20, 20% improvement in the Assessments in Ankylosing Spondylitis Response Criteria; CRP, C
reactive protein; TCZ, tocilizumab; ULN, upper limit of normal.</p></td>
</tr>
</tbody>
</table>
